NO20076325L - Dispersible bosertan tablet - Google Patents

Dispersible bosertan tablet

Info

Publication number
NO20076325L
NO20076325L NO20076325A NO20076325A NO20076325L NO 20076325 L NO20076325 L NO 20076325L NO 20076325 A NO20076325 A NO 20076325A NO 20076325 A NO20076325 A NO 20076325A NO 20076325 L NO20076325 L NO 20076325L
Authority
NO
Norway
Prior art keywords
dispersible
bosertan
tablet
benzenesulfonamide
pyrimidin
Prior art date
Application number
NO20076325A
Other languages
English (en)
Other versions
NO339781B1 (no
Inventor
Lovelace Holman
Timm Trenktrog
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076325(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20076325L publication Critical patent/NO20076325L/no
Publication of NO339781B1 publication Critical patent/NO339781B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører dispergerbare tabletter omfattende forbindelsen 4- tert-butyl-N-[6-(2-hydroksy-etoksy)-5-(2-metoksy-fenoksy)-2-(pyrimidin-2-yl)-pyrimidin- 4-yl]-benzensulfonamid.
NO20076325A 2005-05-17 2007-12-10 Dispergerbar tablett NO339781B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005005367 2005-05-17
PCT/IB2006/051519 WO2006123285A2 (en) 2005-05-17 2006-05-15 Dispersible bosertan tablet

Publications (2)

Publication Number Publication Date
NO20076325L true NO20076325L (no) 2008-02-04
NO339781B1 NO339781B1 (no) 2017-01-30

Family

ID=37431647

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076325A NO339781B1 (no) 2005-05-17 2007-12-10 Dispergerbar tablett

Country Status (23)

Country Link
US (3) US7959945B2 (no)
EP (1) EP1883397B1 (no)
JP (1) JP4219399B2 (no)
KR (2) KR20080014002A (no)
CN (1) CN101175484B (no)
AT (1) ATE451914T1 (no)
AU (1) AU2006248593B2 (no)
BR (1) BRPI0610187B8 (no)
CA (1) CA2607098C (no)
CY (1) CY1110610T1 (no)
DE (1) DE602006011150D1 (no)
DK (1) DK1883397T3 (no)
ES (1) ES2336943T3 (no)
IL (1) IL187383A (no)
MX (1) MX2007014454A (no)
NO (1) NO339781B1 (no)
NZ (1) NZ564167A (no)
PL (1) PL1883397T3 (no)
PT (1) PT1883397E (no)
RU (2) RU2404774C2 (no)
SI (1) SI1883397T1 (no)
WO (1) WO2006123285A2 (no)
ZA (1) ZA200710903B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1883397T1 (sl) 2005-05-17 2010-04-30 Actelion Pharmaceuticals Ltd Disperzibilne tablete bosertana
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8785461B2 (en) 2008-02-08 2014-07-22 Generics [Uk] Limited Process for preparing bosentan
EP2350028A1 (en) 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104487057A (zh) 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
KR101451327B1 (ko) * 2013-01-08 2014-11-03 안국약품 주식회사 보센탄의 제어방출성 다층 정제 및 그 제조방법
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
CN104840965B (zh) * 2015-05-05 2018-05-08 重庆华邦制药有限公司 波生坦的制剂及其稳定剂
KR20160141045A (ko) 2015-05-27 2016-12-08 한올바이오파마주식회사 보센탄을 함유한 약학적 조성물
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN108703956A (zh) * 2018-08-21 2018-10-26 天津双硕医药科技有限公司 一种含有波生坦的固体药物组合物
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
TR2021019265A2 (tr) * 2021-12-07 2023-06-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Bosentan farmasötik bileşimleri.
WO2023128902A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising bosentan and relevant excipients
WO2023130028A1 (en) 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
CN114533738A (zh) * 2022-02-19 2022-05-27 苏州海景医药科技有限公司 一种波生坦固体药物组合物及其制备方法
WO2026007874A1 (zh) * 2024-07-02 2026-01-08 亚宝药业集团股份有限公司 一种波生坦微片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US6635648B2 (en) * 2000-08-18 2003-10-21 Queen's University At Kingston Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
US7192962B2 (en) * 2002-05-31 2007-03-20 Schering Corporation Xanthine phosphodiesterase V inhibitor polymorphs
CA2412856A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
KR100604034B1 (ko) 2003-10-08 2006-07-24 주식회사유한양행 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
SI1883397T1 (sl) 2005-05-17 2010-04-30 Actelion Pharmaceuticals Ltd Disperzibilne tablete bosertana

Also Published As

Publication number Publication date
ES2336943T3 (es) 2010-04-19
KR20080014002A (ko) 2008-02-13
RU2010129460A (ru) 2012-01-27
NO339781B1 (no) 2017-01-30
US20130023547A1 (en) 2013-01-24
CN101175484A (zh) 2008-05-07
PT1883397E (pt) 2010-02-23
BRPI0610187B8 (pt) 2021-05-25
ZA200710903B (en) 2008-12-31
WO2006123285A2 (en) 2006-11-23
CA2607098A1 (en) 2006-11-23
US7959945B2 (en) 2011-06-14
US8309126B2 (en) 2012-11-13
BRPI0610187A2 (pt) 2010-06-01
BRPI0610187B1 (pt) 2020-03-03
KR20100093105A (ko) 2010-08-24
RU2404774C2 (ru) 2010-11-27
HK1120212A1 (en) 2009-03-27
DK1883397T3 (da) 2010-04-06
IL187383A0 (en) 2008-02-09
AU2006248593B2 (en) 2011-03-17
RU2007146395A (ru) 2009-06-27
CY1110610T1 (el) 2015-04-29
MX2007014454A (es) 2008-02-07
WO2006123285A3 (en) 2007-07-05
CN101175484B (zh) 2012-02-01
CA2607098C (en) 2012-04-10
IL187383A (en) 2011-09-27
PL1883397T3 (pl) 2010-05-31
EP1883397A2 (en) 2008-02-06
EP1883397B1 (en) 2009-12-16
AU2006248593A1 (en) 2006-11-23
SI1883397T1 (sl) 2010-04-30
JP2008540512A (ja) 2008-11-20
US20110245281A1 (en) 2011-10-06
JP4219399B2 (ja) 2009-02-04
NZ564167A (en) 2009-12-24
US20080193528A1 (en) 2008-08-14
ATE451914T1 (de) 2010-01-15
DE602006011150D1 (de) 2010-01-28

Similar Documents

Publication Publication Date Title
IL187383A0 (en) Dispersible bosertan tablet
MX2025013699A (es) Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak
AR112118A2 (es) Inhibidores de pi-3 quinasa
DK2004641T3 (da) HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
UY29500A1 (es) Proceso quimico
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
LTC2203431I2 (lt) Priešinfekciniai pirimidinai ir jų panaudojimas
HRP20041177B1 (hr) Mikrobicidni pirimidini ili triazini za prevenciju prijenosa hiv seksualnim putem
CL2007002948A1 (es) Hidratos del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluor-n-((metil(1-metiletil)amino)sulfonil]benzamida; proceso para la preparacion de dicho hidrato; composicion fitoprotectora; y metodo para con
NO2014029I2 (no) Sofosbuvir. (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)-(fenoksy)fosforylamino)propanoat
HRP20110094T8 (en) Solid preparation comprising alogliptin and pioglitazone
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
GEP20125564B (en) Pyrimidine derivatives as kinase inhibitors
DK2203444T3 (da) Faste former af (S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chlor-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
TN2010000070A1 (en) Fused bicyclic pyrimidines
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
ATE420646T1 (de) Aminopyrimidine als kinase-modulatoren
TR201903012T4 (tr) Bosentan monohidratın ve bunun ara ürünlerinin hazırlanması için proses.
IL182419A0 (en) Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
TH102392B (th) การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส